Animal models of systemic lupus UNIT 5.60 Erythematosus (SLE) and ex vivo assay design for drug discovery

Current Protocols in Pharmacology

Volumn , Issue SUPPL. 53, 2011, Pages

  Seavey, Matthew M ^a   Lu, Lily D ^a   Stump, Kristine L ^a  

^a CEPHALON INC   (United States)

Author keywords

Animal models; Drug discovery; Lupus; Sle

Indexed keywords

ANTINUCLEAR ANTIBODY; BORTEZOMIB; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY CD45R; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CHROMATIN; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HISTOLOGY; IN VITRO STUDY; KIDNEY FUNCTION TEST; MODEL; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; URINALYSIS;

EID: 80053518060     PISSN: 19348282     EISSN: 19348290     Source Type: Journal    
DOI: 10.1002/0471141755.ph0560s53     Document Type: Article

References (63)

1. Alperovich, G., Rama, I., Lloberas, N., Franquesa, M., Poveda, R., Gomá, M., Herrero-Fresneda, I., Cruzado, J.M., Bolaños, N., Carrera, M., Grinyó, J.M., and Torras, J. 2007. New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 16:18-24.
2. Asanuma, Y., Nagai, K., Kato, M., Sugiura, H., and Kawai, S. 2002. Weekly pulse therapy of methotrexate improves survival compared with its daily administration inMRL/lpr mice. Eur. J. Pharmacol. 435:253-258.
3. Asensi, V., Kimeno, K., Kawamura, I., Sakumoto, M., and Nomoto, K. 1989. Treatment of autoimmune MRL/lpr mice with anti-B220 monoclonal antibody reduces the level of anti-DNA antibodies and lymphadenopathies. Immunology 68:204-208.
4. Assassi, S., Mayes, M.D., Arnett, F.C., Gourh, P., Agarwal, S.K., McNearney, T.A., Chaussabel, D., Oommen, N., Fischbach, M., Shah, K.R., Charles, J., Pascual, V., Reveille, J.D., and Tan, F.K. 2010. Systemic sclerosis and lupus: Points in an interferon-mediated continuum. Arthritis Rheum. 62:589-598.
5. Bancroft, J.D. and Gamble, M. 2007. Theory and Practice of Histological Techniques, Churchill Livingstone, New York.
6. Bertsias, G. and Boumpas, D.T. 2008. Update on themanagement of lupus nephritis: Let the treatment fit the patient. Nat. Clin. Pract. Rheumatol. 4:464-472.
7. Chun, H.Y., Chung, J.W., Kim, H.A., Yun, J.M., Jeon, J.Y., Ye, Y.M., Kim, S.H., Park, H.S., and Suh, C.H. 2007. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J. Clin. Immunol. 27:461-466.
8. Cohen, P.L. and Maldonado, M.A. 2002. Animal models for SLE. Curr. Protoc. Immunol. 52:15.20.1-15.20.22.
9. Cooper, G.S., Makris, S.L., Nietert, P.J., and Jinot, J. 2009. Evidence of autoimmune-related effects of trichloroethylene exposure from studies in mice and humans. Environ. Health Perspect. 117:696-702.
10. Crowther, J.R. 2000. The ELISA Guidebook, Humana Press, Totowa, N.J.
11. Davidson, A. and Aranow, C. 2010. Lupus nephritis: Lessons from murine models. Nat. Rev. Rheumatol. 6:13-20.
12. Donovan, J. and Brown, P. 2006a. Blood collection. Curr. Protoc. Immunol. 73:1.7.1-1.7.9.
13. Donovan, J. and Brown, P. 2006b. Animal identification. Curr. Protoc. Immunol. 73:1.5.1-1.5.4.
14. Dubois, E.L., Horowitz, R.E., Demopoulos, H.B., and Teplitz, R. 1966. NZB/NZW mice as a model of systemic lupus erythematosus. JAMA 195:285-289.
15. Egner, W. 2000. The use of laboratory tests in the diagnosis of SLE. J. Clin. Pathol. 53:424-432.
16. Fairhurst, A.M., Wandstrat, A.E., and Wakeland, E.K. 2006. Systemic lupus erythematosus:Multiple immunological phenotypes in a complex genetic disease. Adv. Immunol. 92:1-69.
17. Fujii, T., Okada, M., Fujita, Y., Sato, T., Tanaka, M., Usui, T., Umehara, H., and Mimori, T. 2009. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice. J. Autoimmun. 33:125-134.
18. Furukawa, F. andYoshimasu, T. 2005. Animal models of spontaneous and drug-induced cutaneous lupus erythematosus. Autoimmun. Rev. 4:345-350.
19. Furukawa, F., Imamura, S., and Takigawa,M. 1995. FK506: Therapeutic effects on lupus dermatoses in autoimmune-prone MRL/Mp-lpr/lpr mice. Arch. Dermatol. Res. 287:558-563.
20. Gounarides, J.S., Korach-André, M., Killary, K., Argentieri, G., Turner, O., and Laurent, D. 2008. Effect of dexamethasone on glucose tolerance and fat metabolism in a diet-induced obesity mouse model. Endocrinology 149:758-766.
21. Graham, R.R., Hom, G.,Ortmann,W., and Behrens, T.W. 2009. Reviewof recent genome-wide association scans in lupus. J. Intern. Med. 265:680-688.
22. Hornbeck, P. 1991. Enzyme-linked immunosorbent assays. Curr. Protoc. Immunol. 1:2.1.1-2.1.22.
23. Houssiau, F.A. and Ginzler, E.M. 2008. Current treatment of lupus nephritis. Lupus 17:426-430.
24. Ichikawa, T., Muchamuel, T., Jiang, J., Owen, T., Kirk, C.J., and Anolik, J.H. 2009. Novel Proteasome Inhibitors Have a Beneficial Effect in Murine Lupus. ACR/ARHP Scientific Meeting, American College of Rheumatology Annual Meeting, Philadelphia. Izui, S., Ibnou-Zekri, N., Fossati-Jimack, L., and Iwamoto, M. 2000. Lessons from BXSB and related mouse models. Int. Rev. Immunol. 19:447-472.
25. Jørgensen, T.N., Gubbels, M.R., and Kotzin, B.L. 2004. New insights into disease pathogenesis from mouse lupus genetics. Curr. Opin. Immunol. 16:787-793.
26. Kelley, J.M., Edberg, J.C., andKimberly, R.P. 2010. Pathways: Strategies for susceptibility genes in SLE. Autoimmun. Rev. 9:473-476.
27. Kiss, E., Lakos, G., Szegedi, G., Poor, G., and Szodoray, P. 2009. Anti-nuscleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity 42:393-398.
28. Kuroda, Y., Ono, N., Akaogi, J., Nacionales, D.C., Yamasaki, Y., Barker, T.T., Reeves, W.H., and Satoh, M. 2006. Induction of lupus-related specific autoantibodies by non-specific inflammation caused by an intraperitoneal injection of n-hexadecane in BALB/c mice. Toxicology 218:186-196.
29. Lacotte, S., Dumortier, H., Décossas, M., Briand, J.P., and Muller, S. 2010. Identification of new pathogenic players in lupus: Autoantibody-secreting cells are present in nephritic kidneys of (NZBxNZW)F1 mice. J. Immunol. 184:3937-3945.
30. Le Hir, M. 2004. Histopathology of humorally mediated anti-glomerular basement membrane (GBM) glomerulonephritis in mice. Nephrol. Dial. Transplant. 19:1875-1880.
31. Looney, R.J. 2010. B cell-targeted therapies for systemic lupus erythematosus: An update on clinical trial data. Drugs 70:529-540.
32. Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265-275.
33. Lu, L.K.L.S., Ruggeri, B.A., and Seavey, M.M. 2010. Novel method of measuring trace cytokines and phosphorylated STAT molecules in the paws of arthritic mice using multiplex bead technology. J. Immunol. Methods. 11:55.
34. McCombe, P.A., Greer, J.M., and Mackay, I.R. 2009. Sexual dimorphism in autoimmune disease. Curr. Mol. Med. 9:1058-1079.
35. Morel, L. 2010. Genetics of SLE: Evidence from mouse models. Nat. Rev. Rheumatol. 6:348-357.
36. Neubert, K., Meister, S., Moser, K., Weisel, F., Maseda, D., Amann, K., Wiethe, C., Winkler, T.H., Kalden, J.R., Manz, R.A., and Voll, R.E. 2008. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14:748-755.
37. Niederer, H.A., Clatworthy, M.R.,Willcocks, L.C., and Smith, K.G. 2010. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann. N.Y. Acad. Sci. 1183:69-88.
38. Nihtyanova, S.I. and Denton, C.P. 2010. Autoantibodies as predictive tools in systemic sclerosis. Nat. Rev. Rheumatol. 6:112-116.
39. Okazaki, H., Hirata, D., Kamimura, T., Sato, H., Iwamoto, M., Yoshio, T., Masuyama, J., Fujimura, A., Kobayashi, E., Kano, S., and Minota, S. 2002. Effects of FTY720 in MRLlpr/ lpr mice: Therapeutic potential in systemic lupus erythematosus. J. Rheumatol. 29:707-716.
40. Ortega, L.M., Schultz, D.R., Lenz, O., Pardo, V., and Contreras, G.N. 2010. Review: Lupus nephritis: Pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 19:557-574.
41. Paulino, A.C. andReddy, S.P. 1996. Splenic irradiation in the palliation of patientswith lymphoproliferative and myeloproliferative disorders. Am. J. Hosp. Palliat. Care 13:32-35.
42. Price, K., Knupp, C.J., Tatum, A.H., Jiang, F., Stoll, M., and Gavalchin, J. 2002. Molecular identification of pathogenetic IdLNF+1 autoantibody idiotypes derived from theNZBxSWRF1 model for systemic lupus erythematosus. J. Autoimmun. 19:87-101.
43. Rahman, A. and Isenberg, D.A. 2008. Systemic lupus erythematosus. N. Engl. J. Med. 358:929-939.
44. Reeves,W.H., Lee, P.Y.,Weinstein, J.S., Satoh, M., and Lu, L. 2009. Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol. 30:455-464.
45. Rigby, R.J. andVyse, T.J. 2004. Models of systemic lupus erythematosus. Drug Discov. Today: Disease Models 1:445-449.
46. Rigby, R.J., Rozzo, S.J., Boyle, J.J., Lewis, M., Kotzin,B.L., andVyse, T.J. 2004. Newloci from New Zealand Black and New Zealand White mice on chromosomes 4 and 12 contribute to lupus-like disease in the context of BALB/c. J. Immunol. 172:4609-4617.
47. Russo, A., Bronte, G., Fulfaro, F., Cicero, G., Adamo, V., Gebbia, N., and Rizzo, S. 2010. Bortezomib: A new pro-apoptotic agent in cancer treatment. Curr. Cancer Drug Targets 10:55-67.
48. Satoh, M., Richards, H.B., Shaheen, V.M., Yoshida, H., Shaw, M., Naim, J.O., Wooley, P.H., and Reeves, W.H. 2000. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin. Exp. Immunol. 121:399-405.
49. Satoh, M., Kuroda, Y., Yoshida, H., Behney, K.M., Mizutani, A., Akaogi, J., Nacionales, D.C., Lorenson, T.D., Rosenbauer, R.J., and Reeves, W.H. 2003. Induction of lupus autoantibodies by adjuvants. J. Autoimmun. 21:1-9.
50. Smith, D.L., Dong, X., Du, S., Oh, M., Singh, R.R., and Voskuhl, R.R. 2007. A female preponderance for chemically induced lupus in SJL/Jmice. Clin. Immunol. 122:101-107.
51. Smith-Bouvier, D.L., Divekar, A.A., Sasidhar, M., Du, S., Tiwari-Woodruff, S.K., King, J.K., Arnold, A.P. Singh, R.R., and Voskuhl, R.R. 2008. A role for sex chromosome complement in the female bias in autoimmune disease. J. Exp. Med. 205:1099-1108.
52. Sontheimer, R.D., McCauliffe, D.P., Zappi, E., and Targoff, I. 1992. Antinuclear antibodies: Clinical correlations and biologic significance. Adv. Dermatol. 7:3-52.
53. Stichweh, D., Pascual, V., and Banchereau, J. 2006. Recent advances in therapeutic strategies for SLE. Drug Discov. Today: Therapeutic Strategies 2:5-10.
54. Sun, K.H., Liu, W.T., Tsai, C.Y., Tang, S.J., Han, S.H., and Yu, C.L. 1995. Anti-dsDNA antibodies cross-react with ribosomal P proteins expressed on the surface of glomerular mesangial cells to exert a cytostatic effect. Immunology 85:262-269.
55. Swaak, A.J., Huysen, V., Nossent, J.C., and Smeenk, R.J. 1990. Antinuclear antibody profiles in relation to specific diseasemanifestations of systemic lupus erythematosus. Clin. Rheumatol. 9:82-94.
56. Tholouli, E., Sweeney, E., Barrow, E., Clay, V., Hoyland, J.A., and Byers, R.J. 2008. Quantum dots light up pathology. J. Pathol. 216:275-285.
57. Turkel, S.B., Miller, J.H., and Reiff, A. 2001. Case series: Neuropsychiatric symptoms with pediatric systemic lupus erythematosus. J. Am. Acad. Child Adolesc. Psychiatry 40:482-485.
58. Weintraub, J.P., Godfrey, V., Wolthusen, P.A., Cheek, R.L., Eisenberg, R.A., and Cohen, P.L. 1998. Immunological and pathological consequences of mutations in both Fas and Fas ligand. Cell. Immunol. 186:8-17
59. Yoshida, H., Satoh, M., Behney, K.M., Lee, C.G., Richards, H.B., Shaheen, V.M., Yang, J.Q., Singh, R.R., and Reeves, W.H. 2002. Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice. Arthritis Rheum. 46:2235-2244.
60. Young, B., Lowe, J.S., Stevens, A., Heath, J.W., and Deakin, P.J. 2006. Wheater's Functional Histology: A Text and Colour Atlas. Churchill Livingstone, New York.
61. Zeller, R. 1989. Fixation, embedding, and sectioning of tissues, embryos, and single cells. Curr. Protoc. Mol. Biol. 7:14.1.1-14.1.8.
62. Zhao, Z., Weinstein, E., Tuzova, M., Davidson, A., Mundel, P., Marambio, P., and Putterman, C. 2005. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum. 52:522-530.
63. Zuckerman, S.H., Evans, G.F., and Bryan, N. 1997. Chronic administration of dexamethasone results in Fc receptor up-regulation and inhibition of class I antigen expression on macrophages from MRL/lpr autoimmune mice. Clin. Diagn. Lab. Immunol. 4:572-578.